Royalty Pharma (RPRX) Divestments (2020 - 2025)
Royalty Pharma (RPRX) has disclosed Divestments for 6 consecutive years, with $5.0 million as the latest value for Q4 2025.
- Quarterly Divestments rose 53.95% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $104.6 million through Dec 2025, up 352.47% year-over-year, with the annual reading at $105.1 million for FY2025, 344.77% up from the prior year.
- Divestments hit $5.0 million in Q4 2025 for Royalty Pharma, up from $905000.0 in the prior quarter.
- In the past five years, Divestments ranged from a high of $62.4 million in Q2 2025 to a low of $905000.0 in Q3 2025.
- Historically, Divestments has averaged $12.3 million across 5 years, with a median of $5.0 million in 2024.
- Biggest YoY gain for Divestments was 1500.0% in 2025; the steepest drop was 91.77% in 2025.
- Year by year, Divestments stood at $6.2 million in 2021, then dropped by 6.45% to $5.8 million in 2022, then decreased by 19.71% to $4.7 million in 2023, then tumbled by 30.34% to $3.2 million in 2024, then skyrocketed by 53.95% to $5.0 million in 2025.
- Business Quant data shows Divestments for RPRX at $5.0 million in Q4 2025, $905000.0 in Q3 2025, and $62.4 million in Q2 2025.